Clinical Outcomes of Transarterial Chemoembolization Combined with Hypofraction Radiation Therapy for Unresectable Large Hepatocellular Carcinoma
Juanjuan Shen1, Nanbao Zhong1, Zhonghua Chen1, Danyun Ma1, Jianhai Lin11Department of Tumor Radiotherapy, 900th Hospital of PLA, The West of the Second Circle Road of Fuzhou, Fujian, China,
Objectives: Aims to evaluate the impact of transarterial chemoembolization (TACE) combined with ?-ray hypofraction radiation therapy (TACE-hRT) for unresectable large hepatocellular carcinoma (ULHCC) and compare the feasibility and efficacy of ULHCC treated by TACE-hRT in supine and prostrate position by turns (TACE-hRTt) with TACE-hRT alone in supine or prostrate position (TACE-hRTa). Methods: The enrolled ULHCC patients (n=141) were treated with TACE-hRTa (n=59) and TACE-hRTt (n=82). The clinical outcomes were retrospectively analyzed and a comparison was made between two treatment modalities. Results: The median progress free survival (PFS) and overall survival (OS) were 13.4 and 14.6 months for all enrolled patients, 7.9 months and 11.8 months for TACE-hRTa patients, 16.8 months and 18.3 months for TACE-hRTt patients, respectively. The OS rates of 1-, 3- and 5-year were 54.6%, 19.1%, 7.8% for all patients, 45.8%, 13.6%, 3.4% for TACE-hRTa patients and 61.1%, 23.2%, 11.2% for TACE-hRTt patients, respectively. No worse than grade 3 adverse effects (AEs) observed in all patients. Conclusion: TACE-hRT is a feasible and efficient treatment modality for ULHCC. The modified modality of TACE-hRTt improves therapeutic responses and outcomes of ULHCC, compared to the TACE-hRTa. Higher marginal dose repre sents a predictor for the superior OS of patients with ULHCC. Keywords: Clinical outcome, Hypofraction radiation therapy, Hepatocellular carcinoma, Transarterial chemoembolization, ?-ray
Cite This Article
Shen J, Zhong N, Chen Z, Ma D, Lin J. Clinical Outcomes of Transarterial Chemoembolization Combined with Hypofraction Radiation Therapy for Unresectable Large Hepatocellular Carcinoma. EJMO. 2023; 7(4): 388-395
Corresponding Author: Nanbao Zhong